Traws Pharma, INC 8-K filings

Traws Pharma received a notification from Nasdaq regarding its non-compliance with the minimum bid price requirement, with 180 days to regain compliance.

Traws Pharma, Inc. has filed a Form 8-K detailing an At-The-Market (ATM) offering of up to $5,575,709 in common stock, pursuant to an effective shelf registration statement.

Traws Pharma, Inc. announced that its stockholders approved an amendment to the 2021 Incentive Compensation Plan, increasing available shares by 2 million and making administrative changes.

Traws Pharma has deferred its Phase 2a human influenza challenge study for tivoxavir marboxil following a negative regulatory review by the UK's MHRA.

Traws Pharma announces advancement of a novel broad-spectrum antiviral agent targeting Hantavirus, Ebola, and Lassa virus outbreaks.

Traws Pharma, Inc. has filed an 8-K detailing an update to its At-The-Market (ATM) offering, with a new prospectus supplement dated May 22, 2026, allowing for the sale of up to $3,128,399 in common stock.

Traws Pharma announced a $60 million private financing to extend operational runway into Q1 2027, with its lead influenza prophylactic candidate, tivoxavir marboxil, advancing towards a human challenge trial and a hantavirus therapy progressing.

Traws Pharma announced a significant private financing of up to $60 million and provided updates on its investigational influenza and COVID-19 therapies, Tivoxavir Marboxil and Ratutrelvir.

Traws Pharma, Inc. announced pricing of a private placement financing expected to yield approximately $10 million to advance its influenza program.

Traws Pharma announced positive Phase 2 results for its COVID-19 treatment ratutrelvir, while its influenza prophylactic tivoxavir marboxil received an FDA clinical hold.

Traws Pharma announced the completion of its ratutrelvir COVID-19 study with promising results and plans for tivoxavir marboxil as a seasonal influenza prophylactic.

Traws Pharma filed a U.S. IND for tivoxavir marboxil for influenza and reported positive interim results for ratutrelvir in COVID-19 patients.

Traws Pharma announced positive interim Phase 2 data for its ritonavir-free COVID-19 treatment, ratutrelvir, showing a differentiated profile versus PAXLOVID.

Traws Pharma's Compensation Committee approved significant stock option and restricted stock unit grants to its executive officers, aligning incentives with shareholder value.

Traws Pharma, Inc. stockholders approved an amended incentive compensation plan, increasing share reserves by 1.5 million, and re-elected all seven director nominees at its 2025 Annual Meeting.

Traws Pharma reports Q3 2025 financial results, highlighting progress in its ratutrelvir and tivoxavir marboxil antiviral programs, significant cost reductions, and key management appointments.

Traws Pharma's Compensation Committee approved stock option grants to its executive officers, including the CEO, CFO, CSO, CMO, and COO.

Traws Pharma initiates Phase 2 trials for ratutrelvir, a ritonavir-free COVID treatment, with results expected by year-end 2025.

Traws Pharma, Inc. announced the appointment of Dr. John Leaman as an independent director and the formalization of Iain Dukes as CEO and Charles Parker as CFO, enhancing corporate governance and leadership.

Traws Pharma, Inc. has completed the acquisition of a pyrrolidine antiviral compound program from Viriom, Inc. for $2.35 million in cash.

Traws Pharma received approval to begin Phase 2 studies for its ritonavir-free COVID-19 treatment, ratutrelvir, with top-line data expected by year-end 2025, while also progressing its single-dose bird flu candidate.

Traws Pharma announced its second quarter 2025 financial results and provided updates on its prioritized antiviral programs for COVID-19 and influenza.

Traws Pharma, Inc. announced the resignation of Interim CFO Nora Brennan and the appointment of Charles Parker as her successor, effective July 5, 2025.

Traws Pharma, a clinical-stage biopharmaceutical company, announced multiple regulatory submissions for its antiviral pipeline, including Phase 2 protocols for its bird flu/seasonal flu and COVID-19 drug candidates, Tivoxavir marboxil and Ratutrelvir, respectively.

Traws Pharma, a biopharmaceutical company primarily focused on respiratory viral diseases, announced highly positive clinical efficacy data for its legacy oncology drug, rigosertib, in patients with recessive dystrophic epidermolysis bullosa associated squamous cell carcinoma (RDEB-SCC), while also highlighting its narazaciclib program and the company's intent to find development and commercialization partners for both assets.

Traws Pharma, Inc. announced it has received detailed guidance from the FDA regarding the development of its investigational bird flu and seasonal flu product candidate, tivoxavir marboxil, and is initiating discussions for national and international stockpiling.

Traws Pharma, Inc. released a new corporate presentation on May 19, 2025, outlining its focus on developing antiviral drugs for respiratory viruses, particularly bird flu and COVID-19.

Traws Pharma reports Q1 2025 financial results and provides business highlights, including updates on its tivoxavir marboxil (TXM) and ratutrelvir antiviral programs.

Traws Pharma formalizes its employment agreement with Interim CEO Iain Dukes and announces the appointment of Jack Stover as the new Chairman of the Board.

Traws Pharma, Inc. announces the offering of up to $7.4 million in common stock through an at-the-market offering agreement with Citizens JMP Securities, LLC.